GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Deferred Tax Assets / Liabilities | ₹-1,066 Cr | ₹-1,049 Cr | ₹-1,805 Cr | ₹-1,655 Cr | ₹-1,506 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Deferred Tax Assets / Liabilities |
---|---|
Mar2025 | ₹-1,066 Cr |
Mar2024 | ₹-1,049 Cr |
Mar2023 | ₹-1,805 Cr |
Mar2022 | ₹-1,655 Cr |
Mar2021 | ₹-1,506 Cr |
How is Deferred Tax Assets / Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Deferred Tax Assets / Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹-1,066 Cr | Negative | |
Mar2024 | ₹-1,049 Cr | Negative | |
Mar2023 | ₹-1,805 Cr | Negative | |
Mar2022 | ₹-1,655 Cr | Negative | |
Mar2021 | ₹-1,506 Cr | - |
Compare Deferred Tax Assets / Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹59,720.6 Cr | 5.5% | 2.6% | 20.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹382,718.0 Cr | 1% | -0.2% | -13.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,282.0 Cr | -2.7% | -2.2% | 17.6% | Stock Analytics | |
CIPLA | ₹125,351.0 Cr | -1.7% | 4.1% | -5.3% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹123,267.0 Cr | 1% | 1.3% | 4.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹107,952.0 Cr | 2.5% | 7.7% | -6.7% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 5.5% |
2.6% |
20.1% |
SENSEX | 1.2% |
0.7% |
-1.5% |
You may also like the below Video Courses